Generalized Pustular Psoriasis Education Initiative Will Improve Care for Patients

The American Academy of Dermatology (AAD) recently announced that it is launching an innovative, powerful project, the Generalized Pustular Psoriasis Education Initiative, to develop educational resources to improve the evaluation, diagnosis, and treatment of patients with generalized pustular psoriasis (GPP).¹

pimentos/AdobeStock

This new program is receiving critical support from Boehringer Ingelheim and is powered by OM1’s data aggregation system and its PhenOM artificial intelligence (AI) platform.The initiative will integrate information from AAD’s DataDerm dermatology patient registrywith the data platform and AI to transform the care of those with GPP.

By connecting DataDerm’s 50 million deidentified patient encounters with OM1’s AI-based Patient Finder tool, dermatology providers can better understand the patient journey, treatment patterns, disease progression, and outcomes.

“The American Academy of Dermatology is committed to excellence in dermatology and finding innovative approaches to improve patient care,” said AAD president Terrence A. Cronin Jr., MD, FAAD, in a press release. “Though rare, GPP can cause patients incredible pain and suffering. While maintaining our focus on patient privacy, this project will break new ground and provide us with resources that will have a significant impact on these patients’ lives.”

The information gathered through the initiative will aid in the development of a range of support systems, including educational resources and tools for dermatology providers, referring physicians, and patients. Through these tools AAD hopes to improve the quality of life for patients with GPP, many of whom experience a delayed diagnosis.

OM1 develops large, electronically connected networks of clinicians and health data in a broad spectrum of specialty areas, including dermatology, rheumatology, mental health, and more. “OM1 is excited to support the American Academy of Dermatology’s work in expanding resources to serve GPP patients,” said Joseph Zabinski, PhD, managing director of AI & Personalized Medicine at OM1 in a press release. “Artificial intelligence is a powerful tool for understanding patterns in rare disease patients’ journeys, and we look forward to using AI to study these journeys in DataDerm to improve outcomes in GPP.”

Findings from the first phase of the project will be shared at the AAD’s 2024 Annual Meeting, March 8 – 12, in San Diego, California.

Reference

1. American Academy of Dermatology launches innovative project to improve outcomes for patients with life-threatening pustular psoriasis. News Release. American Academy of Dermatology Association. Published June 22, 2023. Accessed June 27, 2023. https://www.aad.org/news/aad-generalized-pustular-psoriasis-education-initiative